激动剂诱导的Orai1α和Orai1β的血表达的功能差异
Isaac Jardin1, Sandra Alvarado1, Jose Sanchez-Collado1
1Department of Physiology (Cellular Physiology Research Group), Institute of Molecular Pathology Biomarkers (IMPB), University of Extremadura, Caceres, Spain.
Journal of cellular physiology
|June 19, 2023
概括
储量耗尽触发了Orai1α和Orai1β通道向血膜的移动. 这种贩运独立于细胞质,需要actin细胞骨和ARF6 GTPase.
科学领域:
- 细胞生物学 细胞生物学
- 分子生物学分子生物学
- 离子通道生理学 离子通道生理学
背景情况:
- Orai1形成储存释放激活通道 (CRAC),对细胞功能至关重要.
- 存在两个Orai1变体,Orai1α (长) 和Orai1β (短),Orai1β是由替代翻译启动引起的.
- Orai1主要存在于血中,但也存在于细胞内.
研究的目的:
- 调查Orai1变体在储量耗尽后流入血膜的机制.
- 确定细胞质水平和特定蛋白质在Orai1转位中的作用.
主要方法:
- 利用细胞载入二甲基BAPTA以化细胞内.
- 检查了Orai1β转位在Orai1α的单个和共同表达系统中.
- 评估了使用主导阴性突变物对乙细胞骨和小GTPase ARF6的要求.
主要成果:
- 储量耗尽诱导Orai1α等离子体膜插入独立于细胞质变化.
- 在储存量耗尽后,Orai1β需要与Orai1α共同表达才能转移到血.
- Orai1变体的转位需要完整的actin细胞骨架,并且取决于ARF6活动.
结论:
- 储量耗尽触发了Orai1α和Orai1β到血膜的新型贩运途径.
- 这一途径由细胞内独立机制调节,涉及actin细胞骨和ARF6.
- 这些发现阐明了Orai1在储量耗尽后血膜丰度的动态调节.
相关概念视频
The Two-State Receptor Model
2.0K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.0K
Drug-Receptor Interaction: Agonist
2.6K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.6K
Opioid Receptors: Overview
1.1K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.1K
Adrenergic Receptors: ɑ Subtype
1.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.6K
Spare Receptors
3.6K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
3.6K
Adrenergic Receptors: β Subtype
1.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.8K


